Immix Biopharma to Participate in Upcoming Investor Conferences

Company Overview - Immix Biopharma, Inc. is recognized as the global leader in relapsed/refractory AL Amyloidosis, a severe disease caused by the immune system producing toxic light chains that lead to organ failure and death [2] - The company's lead candidate is NXC-201, a sterically-optimized BCMA-targeted CAR-T cell therapy designed to filter out non-specific activation and teach the immune system to eliminate toxic light chains [2] - NXC-201 is currently being evaluated in a U.S. multi-center study (NEXICART-2) with a registrational design and has received Breakthrough Therapy Designation, Regenerative Medicine Advanced Therapy designation, and Orphan Drug Designation from the FDA and EMA [2] Upcoming Events - Immix Biopharma will present and host investor meetings at institutional investor conferences, including the Leerink Partners 2026 Global Healthcare Conference from March 8-11, 2026, and the Citizens Life Sciences Conference from March 10-11, 2026, both held in Miami Beach, FL [1][3] - Company management will conduct one-on-one meetings during these conferences, and interested investors are encouraged to contact their Leerink or Citizens representative for meeting requests [1]